ContractJoint Research and Development Agreement • March 27th, 2018
Contract Type FiledMarch 27th, 2018Carna Biosciences, Inc. (Head Office: Kobe, Hyogo; President and CEO: Kohichiro Yoshino) (“Carna Biosciences”) and Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Osaka; President and CEO: Masayo Tada) (“Sumitomo Dainippon Pharma”) announced today that, on March 27, 2018, the two companies signed an agreement on joint research with the aim of discovering novel kinase inhibitors for psychiatric and neurological disorders, as well as on the subsequent development and commercialization of such therapeutic agent(s) (hereinafter referred to as the "Agreement").